Provider Compliance Tips for Oral Anticancer Drugs and Antiemetic Drugs Used in Conjunction
This revised Product comprises Subregulatory Guidance for Suppliers of Durable Medical Equipment (DME) sending claims to DME Medicare Administrative Contractors (MACs) and physicians or other practitioners who write prescriptions for oral anticancer drugs and antiemetic drug, and its content is based on publically available content within the Medicare Fee-for-Service 2016 Improper Payments Report at https://www.cms.gov/Research-Statistics-Data-and-Systems/Monitoring-Programs/Medicare-FFS-Compliance-Programs/CERT/Downloads/AppendicesMedicareFee-for-Service2016ImproperPaymentsReport.pdf
Final
Issued by: Centers for Medicare & Medicaid Services (CMS)
Issue Date: May 03, 2021
DISCLAIMER: The contents of this database lack the force and effect of law, except as authorized by law (including Medicare Advantage Rate Announcements and Advance Notices) or as specifically incorporated into a contract. The Department may not cite, use, or rely on any guidance that is not posted on the guidance repository, except to establish historical facts.